

# HAIRCARE



S P E C I F I C F O R M U L A

**NON-CROSS-LINKED  
HYALURONIC ACID 2 mg**



**RESTRUCTURING HAIR  
COMPLEX\***



### **BENEFITS**

- Hair loss is slowed down,
- Hair texture is improved,
- Scalp is deeply hydrated,
- Dandruff is eliminated.

\* Zinc, Arginine, Cysteine, Glutamine, Glycine, Ornithine, Biotin, Calcium Pantothenate, Cyanocobalamin, Folic Acid, Nicotinamide, Pyridoxine.

*La Beauté commence par la qualité de la peau. N.S.*

REVITACARE is a French laboratory founded in 2003, with the conviction that "Beauty starts with skin quality".

We develop medical devices and sterile cosmetics with highly elaborated formulas combining hyaluronic acid and specific complex for aesthetic doctors and professionals to prevent and correct skin aging effects and treat hair problems.

## QUALITY • SECURITY • EFFICIENCY

Our medical devices are CE marked and comply with the essential requirements of the Council Directive 93/42/EEC concerning medical devices and its amendments.

REVITACARE : EN ISO 13485 certified

LABORATOIRE  
**REVITACARE**  
FRANCE

Made in France

21, avenue de l'Eguillette - Parc d'Activités du Vert Galant  
95310 Saint Ouen l'Aumône - FRANCE  
Tel: +33 (0) 1 30 37 31 45 - Email: [contact@revitacare.fr](mailto:contact@revitacare.fr)

[www.revitacare.net](http://www.revitacare.net)

# HAIRCARE




LABORATOIRE  
**REVITACARE**  
FRANCE



## HAIRCARE decreases hair loss\*

BEFORE AFTER 6 SESSIONS




**CASE 1: male patient**  
After 2 months hair growth is visible.




**CASE 2: male patient**  
After 2 months hair loss is slowed down and hair regrowth is observed.



**CASE 3: male patient**  
After 2 months hair regrowth is observed.



**CASE 4: female patient**  
At the end of protocol, hair density is increased.



**CASE 5: male patient**  
At the end of protocol, hair density is increased.

REVITACARE © 2018 SOURCE

\* Visible results depend on life cycle of hair.

## REDISCOVER HAIR BEAUTY

Treatment of various scalp & hair problems for both women and men:

- hair loss,
- dehydration of the scalp and presence of dandruff,
- hair breakage.

### HAIRCARE ACTS ON 3 TARGETS

- **HAIR FOLLICLE**  
It becomes more resistant and its anchoring is reinforced into the scalp.  
**Hair loss is slowed down.**
- **SCALP**  
Scalp is deeply hydrated.  
**Dandruff is eliminated.**
- **HAIR TEXTURE**  
Hair texture is improved.  
**Hair regains strength.**

### CHARACTERISTICS

- Case: 10 vials x 5mL
- Sterilization: aseptic filtration
- Pyrogen free

**PRACTITIONERS SATISFACTION**  
satisfied or highly satisfied by HAIRCARE results\*

93,2% hair loss decrease  
89,5% scalp hydration  
80,7% scalp cleansing  
91,6% hair texture



**PATIENTS SATISFACTION**  
satisfied or highly satisfied by HAIRCARE results\*

94,9% hair loss decrease  
82,6% scalp hydration  
83,2% scalp cleansing  
93,0% hair texture

\* Multicentric clinical register on 122 patients - Satisfaction upon protocol completion (6 sessions at intervals of 6 to 10 days)

### PROTOCOL



- Injection into the superficial dermis of the scalp, near the hair roots.
- Manual injections with 30G needles.
- Techniques: nappage, point by point.
- Protocol: 6 sessions of injections of the content of one vial maximum every 6 - 10 days. For long-lasting result, the practitioner decides on touch-up treatment depending on the severity of the case.
- Read carefully the instructions for use before using the product.

HAIRCARE is a sterile single use medical device class III (CE 0123) manufactured by REVITACARE, indicated to improve quality of hair and scalp by restoring hydration, and to reduce hair loss by anchoring it. For medical use. Read carefully HAIRCARE leaflet before using the product. HAIRCARE must be injected in an aseptic manner, by duly doctor with knowledge of the injection site, with sterile and single use equipment, which is not supplied by REVITACARE. Before using HAIRCARE, check the expiry date on the label of the vial, the integrity of the vial and the appearance of the solution. Store between 2°C and 30°C, away from the light in its original secondary packaging. Do not use if package is damaged. Once the vial of HAIRCARE has been opened use it immediately and discard the vial and the remaining product after use, complying with the procedures in force in the establishment. Single use solution: do not re-sterilise and do not re-use. The doctor must inform the patient that there are potential adverse effects linked to the injection of this device, which occur immediately or are delayed. Adverse events observed with HAIRCARE: - pain and bleeding during the injection, tingling, redness and headache - Low efficacy. The patient must inform the doctor as soon as possible if any other adverse events persist for longer than one week. The practitioner must remedy it by an appropriate treatment. The distributor and / or manufacturer must be alerted to any other adverse event related to the injection of HAIRCARE. Other adverse effects observed with a very low frequency in the literature concerning alopecia treatment: oedema, erythema and inflammation. This medical device is not reimbursed by health insurance organisation. This medical device is a regulated health product which, under this regulation, bears the CE marking.